Research
Hormonal
Obesity-induced adipose tissue hypoxia and hypertrophy drive a pro-inflammatory adipokine profile (high leptin/TNF-a/IL-6, low adiponectin) that creates a permissive microenvironment for tumor initiation, progression, and metastasis.
Maintaining a healthy weight reduces the risk of obesity-related cancers by preventing the physiological state of adipose hypoxia and chronic inflammation. This involves managing body fat to avoid the hormonal imbalances (high leptin, low adiponectin) that fuel tumor growth.
ModerateSupportsHIGH confidence
Dysfunctional adipose tissue in obesity releases a disturbed profile of adipokines with elevated levels of pro-inflammatory factors and a consequent alteration of key signaling mediators which may be an active local player in establishing the peritumoral environment promoting tumor growth and progression.
Why this rating
This is a review paper summarizing multiple studies; it is not a primary clinical trial.
Source
Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation
Rosa Divella et al. · Journal of Cancer · 2016
DOI 10.7150/jca.16884
narrative_reviewCited 332×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Low levels of adiponectin, common in obesity, remove a protective anti-tumor effect, thereby facilitating cancer development and progression.Moderate
- Elevated leptin levels in obesity promote cancer cell survival, proliferation, and migration by inducing anti-apoptotic, pro-inflammatory, and angiogenic factors.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →